Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, the researchers observed that treatment with intralesional and topical corticosteroids, finasteride, and minoxidil may stop the progression of frontal fibrosing alopecia in postmenopausal and premenopausal women.

This study found that the protein Formin 2 helps regulate cell-to-cell transport in thale cress by stabilizing actin filaments at plasmodesmata, with its absence leading to increased permeability and vulnerability to viral infections.

This study reviewed 38 cases of frontal fibrosing alopecia, observing that diagnosis often occurs years after onset and is more prevalent in postmenopausal women.

Isotretinoin at low doses effectively treats facial papules in frontal fibrosing alopecia.

This study found that treating human skin explants with TPA increased the number of certain melanocyte phenotypes in the interfollicular epidermis, suggesting that this ex vivo model can effectively replicate human skin's pharmacologic responses for studying potential treatments.

In this case report, a young female Indian patient with alopecia areata saw hair regrowth within 2 months of treatment with oral tofacitinib, with continued improvements over a 5-month period and no reported side effects.

This study reported that heterozygosity for FHIT affects mice's susceptibility to spontaneous alopecia areata and to certain preneoplastic lesions induced by benzo[a]pyrene, but does not change how they respond to budesonide and N-acetyl-L-cysteine.

This study of fifty female patients with frontal fibrosing alopecia in Egypt found that it is a complex condition with no definitive treatment, as it often co-occurs with lichen planus and thyroid issues.

This review examines the outcomes of treating Brazilian patients with alopecia universalis using tofacitinib and highlights the need for randomized controlled trials to determine optimal dosing and duration.

In this review, cosmetic practices such as non-ablative lasers, autologous fat injections, and oral isotretinoin may help alleviate certain symptoms of frontal fibrosing alopecia, while treatments like deep chemical peels and ablative laser therapies are contraindicated due to potential scarring risks.

This study found that certain circulating miRNAs in skin and plasma may serve as potential biomarkers for distinguishing frontal fibrosing alopecia from control cases, highlighting the need for further validation in larger cohorts.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

This review investigates the relationship between certain gene polymorphisms associated with obesity (FTO and MC4R) and Polycystic Ovarian Syndrome, reporting no new results but suggesting a potential genetic link.

This case report suggests that tofacitinib may effectively manage symptoms of AGS7 in a patient with an IFIH1 mutation, though further studies are needed to confirm its long-term safety and efficacy.

In this study, researchers identified a recurrent MBTPS2 splice-site variant as a mutational hotspot in IFAP syndrome across diverse families, with phenotype severity suggesting the influence of additional modifiers.

This study suggests that Flightless I may inhibit the activation of epidermal stem cells during wound repair by disrupting Wnt/β-catenin signaling, potentially delaying wound reepithelialization.

This case report highlights an atypical presentation of favus in an immunocompetent adult, where a psoriasiform plaque over the 'bindi' area was successfully treated with systemic itraconazole, achieving complete resolution without relapse. Simple stains proved essential for diagnosis in this resource-limited setting.

This study of alopecia areata patients found that a 10 mg twice-daily dose of oral tofacitinib led to significant hair regrowth, suggesting it may be beneficial for treatment.

This review discusses the potential link between contact allergy and frontal fibrosing alopecia, noting the presence of implicated allergens in current literature, but reports no new clinical findings.

This review compiles existing data on frontal fibrosing alopecia and highlights the promise of 5-alpha reductase inhibitors as a treatment option, while noting the need for clarity on its cause and progression.

Certain drugs and supplements may contribute to hair loss in the frontal hairline in older women.

This study found that follistatin and activin interactions are important for hair follicle development and cycling in mice, suggesting that they may regulate processes involving BMP-2 and its antagonist.

In this study, oral tofacitinib treatment led to significant hair regrowth and changes in skin and blood biomarkers in a patient with alopecia areata.

This study found that chronic exposure to fadrozole or finasteride during frog development induced intersex individuals, which displayed different gene expression profiles depending on the chemical used.

This study found that in a tertiary academic institution, nearly 1 in 5 dermatology consults were for drug-related skin reactions, with antibiotics frequently identified as the culprits.

This study found that CTIP2 is highly expressed in mouse skin during embryogenesis and adulthood, suggesting it may play a role in skin development and homeostasis.

This case report described a 24-year-old with alopecia totalis who saw full scalp hair regrowth by the 9th month while using oral tofacitinib, which was well-tolerated and did not show serious adverse effects. Longer-term studies are needed to confirm its overall effectiveness for alopecia totalis.

This study discovered that the gene Tfap2b identifies a melanocyte stem cell population in zebrafish, essential for regenerating melanocytes with multi-fate potential into adult pigment cells.